Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ESSA Pharma Inc EPIX

Healthcare Biotechnology
ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, EPI-7386, is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). The Company is completing the initial Phase I clinical development of EPI-7386 as a... see more

Recent & Breaking News (NDAQ:EPIX)

ESSA Pharma Provides Clinical Study Update and Announces Presentations at the American Association for Cancer Research Annual Meeting

Canada NewsWire April 3, 2017

ESSA to Present at 29th Annual Roth Conference and Rodman & Renshaw Premier Series - A Future Without Cancer

Canada NewsWire March 14, 2017

ESSA Pharma Inc. Reports Results of Annual General and Special Meeting of Shareholders

PR Newswire March 8, 2017

Noble Capital Markets Initiates Research Coverage on ESSA Pharma Inc. (EPIX)

PR Newswire February 17, 2017

ESSA Pharma Provides Business Update and Announces Financial Results for the First Quarter Ended December 31, 2016

Canada NewsWire February 13, 2017

ESSA Pharma to Present at 2017 BIO CEO & Investor Conference

Canada NewsWire February 10, 2017

ESSA receives US$4.0 million grant payment from Cancer Prevention Research Institute of Texas

Canada NewsWire January 30, 2017

ESSA Pharma Provides Business Update and Announces Fourth Quarter and Year Ended September 30, 2016 Financial Results

Canada NewsWire December 14, 2016

12 Biggest Mid-Day Gainers For Monday

Benzinga.com  November 28, 2016

ESSA Secures US$10 Million Term Loan from Silicon Valley Bank

Canada NewsWire November 21, 2016

ESSA Pharma to present at Rodman & Renshaw 18th Annual Global Investment Conference

Canada NewsWire September 12, 2016

ESSA Pharma Inc. reports financial results for the third quarter June 30, 2016

Canada NewsWire August 12, 2016

ESSA Names Peter Virsik as Executive Vice President & Chief Operating Officer

Canada NewsWire August 1, 2016